Hofheinz, R., Herrle, F., Dechow, T., von Weikersthal, L. F., Welslau, M., Lettmaier, S., . . . Gaiser, T. (2024). mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: A randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). ESMO open, 9(9), . https://doi.org/10.1016/j.esmoop.2024.103703
Chicago-Zitierstil (17. Ausg.)Hofheinz, Ralf-Dieter, et al. "MFOLFOX6 Versus MFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: A Randomized Phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)." ESMO Open 9, no. 9 (2024). https://doi.org/10.1016/j.esmoop.2024.103703.
MLA-Zitierstil (9. Ausg.)Hofheinz, Ralf-Dieter, et al. "MFOLFOX6 Versus MFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: A Randomized Phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)." ESMO Open, vol. 9, no. 9, 2024, https://doi.org/10.1016/j.esmoop.2024.103703.